---
id: longevity-and-healthspan-interventions
name: Longevity & Healthspan Interventions
family: technological
tier: active
url: https://futuremap.talin.digital/e/longevity-and-healthspan-interventions/
license: CC-BY-NC-4.0
---

# Longevity & Healthspan Interventions

## Maturity
1/5 — All human data are early-phase and no biomarker of ageing is accepted by the FDA or EMA as a trial endpoint.

Source: Hickson et al., EBioMedicine 47:446–456 (2019), first-in-human senolytic pilot N=9; UNITY UBX0101 Phase 2 (N=183) missed its primary endpoint, 17 Aug 2020; Ying et al., Nature Aging 4:231–246 (2024) on epigenetic clocks as surrogate endpoints (2019–2024)

## What it is
Interventions aimed at the biology of ageing itself — senolytics, metabolic and cellular reprogramming approaches.

## What it does
It targets the upstream driver of most age-related disease at once, rather than treating each disease separately. If it works even partially, the demographic and fiscal consequences are large.

## Common misconception
That the field has demonstrated human results. Animal data is genuinely striking, human trials are early, and this is among the most overclaimed areas in this Compendium.

## Steepens
- Longevity and the Healthspan Gap (longevity-and-the-healthspan-gap) — large
- The Silver Economy (the-silver-economy) — moderate
- The Care Economy (the-care-economy) — moderate
- Fertility Collapse (fertility-collapse) — marginal

## What would change its gradient
- Validated biomarkers of ageing, which would shorten trials from decades to years
- Regulatory recognition of ageing as an indication
- Nothing on the enthusiasm side — funding is not the constraint here
